Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CAD | P27708 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147075 | 1.00 | TGFBR1 (0.47) | TGFBR1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL12461743 | 0.84 | GNPAT (0.52) | TGFBR1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL2793959 | 0.81 | TGFBR1 (0.68) | TGFBR1FOLH1NAALAD2RIMKLACAD | |
| SCHEMBL2307007 | 0.81 | TGFBR1 (0.68) | TGFBR1FOLH1NAALAD2RIMKLACAD | |
| SCHEMBL2793957 | 0.81 | TGFBR1 (0.68) | TGFBR1FOLH1NAALAD2RIMKLACAD | |
| SCHEMBL7043592 | 0.80 | KMT2A (0.53) | TGFBR1FOLH1NAALAD2RIMKLAKMT2A | |
| SCHEMBL215383 | 0.80 | FOLH1 (0.44) | TGFBR1FOLH1NAALAD2RIMKLAGNPAT | |
| SCHEMBL3282950 | 0.80 | FPR2 (0.46) | TGFBR1FOLH1NAALAD2RIMKLACAD | |
| SCHEMBL5493511 | 0.80 | KMT2A (0.53) | TGFBR1FOLH1NAALAD2RIMKLAKMT2A | |
| SCHEMBL215384 | 0.80 | FOLH1 (0.44) | TGFBR1FOLH1NAALAD2RIMKLAGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884240-B2 | Acylating L- or D-homoserine to produce N-acyl- L and/or D-homoserine lactone, opening the lactone ring and sulfiding with methyl mercaptan in the presence of a basic or acid catalyst, and hydrolyzing the product to remove the acyl group | EVONIK DEGUSSA GMBH (DE) | 2011-02-08 | — | — | US | claimed |
| EP-1976827-A2 | METHOD FOR PRODUCING METHIONINE FROM HOMOSERINE | Evonik Degussa GmbH (DE) | 2008-10-08 | — | — | EP | claimed |
| US-20080146840-A1 | Method for production of methionine from homoserine | DEGUSSA GMBH (DE) | 2008-06-19 | — | — | US | claimed |
| US-7368600-B2 | Method for production of methionine from homoserine | DEGUSSA GMBH (DE) | 2008-05-06 | — | — | US | claimed |
| US-20070190622-A1 | Method for production of methionine from homoserine | DEGUSSA GMBH (DE) | 2007-08-16 | — | — | US | claimed |
| WO-2007085514-A2 | METHOD FOR PRODUCING METHIONINE FROM HOMOSERINE | EVONIK DEGUSSA GMBH (DE) | 2007-08-02 | — | — | WO | claimed |
| CN-112574118-B | Process for preparing glufosinate-hydantoin intermediates and analogues | 利尔化学股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2021057945-A1 | METHOD FOR PREPARING GLUFOSINATE-AMMONIUM HYDANTOIN INTERMEDIATE AND ANALOGUE THEREOF | 利尔化学股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-7884240-B2 | Acylating L- or D-homoserine to produce N-acyl- L and/or D-homoserine lactone, opening the lactone ring and sulfiding with methyl mercaptan in the presence of a basic or acid catalyst, and hydrolyzing the product to remove the acyl group | EVONIK DEGUSSA GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7884240-B2 | Acylating L- or D-homoserine to produce N-acyl- L and/or D-homoserine lactone, opening the lactone ring and sulfiding with methyl mercaptan in the presence of a basic or acid catalyst, and hydrolyzing the product to remove the acyl group | EVONIK DEGUSSA GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7884240-B2 | Acylating L- or D-homoserine to produce N-acyl- L and/or D-homoserine lactone, opening the lactone ring and sulfiding with methyl mercaptan in the presence of a basic or acid catalyst, and hydrolyzing the product to remove the acyl group | EVONIK DEGUSSA GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| EP-1976827-A2 | METHOD FOR PRODUCING METHIONINE FROM HOMOSERINE | Evonik Degussa GmbH (DE) | 2008-10-08 | — | — | EP | disclosed |
| EP-1976827-A2 | METHOD FOR PRODUCING METHIONINE FROM HOMOSERINE | Evonik Degussa GmbH (DE) | 2008-10-08 | — | — | EP | disclosed |
| US-7368600-B2 | Method for production of methionine from homoserine | DEGUSSA GMBH (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20070190622-A1 | Method for production of methionine from homoserine | DEGUSSA GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070190622-A1 | Method for production of methionine from homoserine | DEGUSSA GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070190622-A1 | Method for production of methionine from homoserine | DEGUSSA GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007085514-A2 | METHOD FOR PRODUCING METHIONINE FROM HOMOSERINE | EVONIK DEGUSSA GMBH (DE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085514-A2 | METHOD FOR PRODUCING METHIONINE FROM HOMOSERINE | EVONIK DEGUSSA GMBH (DE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085514-A2 | METHOD FOR PRODUCING METHIONINE FROM HOMOSERINE | EVONIK DEGUSSA GMBH (DE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146840-A1 | Method for production of methionine from homoserine | MTR, BHMT2, BHMT | TGFBR1 4141/4885FOLH1 471/4885NAALAD2 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.